ALCOA+ Data Integrity

ALCOA+ data integrity services for pharmaceutical manufacturers. The engagement covers the data integrity assessment, the remediation roadmap, and the operating routine that maintains data integrity over time.

ALCOA+ principles — all nine attributes

ALCOA+ is the data integrity framework applied by regulatory authorities including FDA, WHO, MHRA, and PIC/S. The original five principles are Attributable (every data record must be linked to the individual who generated or modified it, enforced through unique user logins and secure audit trails), Legible (data must be readable, permanent, and accessible for the required retention period), Contemporaneous (records must be captured in real time at the exact moment an action occurs, with automated and secure timestamps), Original (the first capture of data, or a verified true copy, must be maintained and protected against unauthorised alteration), and Accurate (data must be truthful, error-free, and exactly reflect the action taken, with authorised corrections fully documented). The CCEA extension adds four further attributes: Complete (all data including metadata, failed tests, and out-of-specification results must be retained without selective exclusion), Consistent (data must demonstrate a logical and sequential tracking of events without contradictions), Enduring (records must be stored on durable, reliable media for long-term preservation), and Available (data must be readily accessible for audits, inspections, and internal reviews at any time required).

Common data integrity gaps — six gap types

Based on published FDA Warning Letters and MHRA inspection findings, six gap types recur most frequently. Manual transcription errors arise when data is moved from paper to electronic systems without adequate verification controls, introducing human error into critical records. Shared logins and generic passwords violate the Attributable principle because individual actions cannot be traced to a specific person. Disabled or inadequate audit trails allow silent and untraceable modifications to manufacturing and laboratory records. Backdating and post-dating falsify timestamps and directly violate the Contemporaneous principle. Unvalidated spreadsheets — standard Excel files without lock-down controls, macro validation, or version history — create uncontrolled data environments. Hybrid records mismanagement produces inconsistencies between paper printouts and the underlying electronic raw data, leaving both records in question.

Assessment methodology per PIC/S PI 041-1

Aligning with PIC/S PI 041-1 (Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments, 2021), we apply a risk-based assessment across four steps. Step one is discovery and gap analysis: mapping the entire data lifecycle across all critical GxP systems to identify vulnerabilities and non-compliance with ALCOA+. Step two is risk assessment: evaluating the potential impact of each identified gap on product quality and patient safety, classifying findings by severity. Step three is remediation strategy: defining corrective actions, preventive actions, responsible owners, target dates, and evidence of completion. Step four is governance and training: embedding data management procedures into the Quality Management System and building a sustained culture of compliance across the organisation.

Remediation roadmap

The remediation roadmap translates risk-assessed findings into a prioritised action plan. Short-term actions address the highest-severity ALCOA+ violations: activating audit trails that have been disabled, enforcing unique user authentication, and withdrawing shared credentials. Medium-term actions focus on upgrading system access controls, migrating from unvalidated spreadsheets to validated electronic systems, and reconciling hybrid paper-electronic records. Long-term actions embed preventive controls: periodic data integrity reviews, trend monitoring of audit trail anomalies, and operating routines for sustained compliance. Each action carries an owner, a target date, and defined evidence of completion that can be presented at the next regulatory inspection.

How to use this page

Use this ALCOA+ Data Integrity page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.

Evidence to prepare

For ALCOA+ Data Integrity, prepare the records, owners, risks and decision criteria linked to alcoa+ principles — all nine attributes, common data integrity gaps — six gap types, assessment methodology per pic/s pi 041-1, remediation roadmap. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.

Frequently asked questions

How long does a data integrity assessment take?

For a typical site with 20-50 GxP systems, the data integrity assessment takes 4-6 weeks.

What is the typical outcome of a data integrity engagement?

A well-executed data integrity engagement produces a clear list of findings, a prioritised remediation roadmap, the operating routine for sustained compliance, and the evidence trail for the next inspection.

What are the most commonly cited data integrity gap categories in inspections?

Based on published FDA Warning Letters and MHRA inspection findings, the most frequently cited gap categories are disabled or inadequate audit trails, shared logins that prevent attribution of individual actions, and backdated records that violate the Contemporaneous principle. Unvalidated spreadsheets and hybrid records mismanagement are also recurring findings.